Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Force

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Nature Medicine|March 8, 2008
The weakness of a big heartThomas Force
Circulation Research|January 9, 2010
Introduction to cardiotoxicity review seriesThomas Force
Circulation|March 28, 2012
Double-edged sword of the new cancer therapeuticsThomas Force
Journal of the American College of Cardiology|August 1, 2006
p38 mitogen-activated protein kinase: a future target for heart failure therapy?Risto Kerkela, Thomas Force
Circulation|June 13, 2013
Mechanism-based engineering against anthracycline cardiotoxicityThomas Force, Yibin Wang
Aging|June 28, 2013
Focusing the spotlight on GSK-3 in agingJibin Zhou, Thomas Force
Circulation Research|November 28, 2007
Not all hypertrophy is created equalRonglih Liao, Thomas Force
Drug Discovery Today|July 12, 2008
Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problemThomas Force, Risto Kerkelä
Current Heart Failure Reports|May 11, 2006
Recent insights into cardiac hypertrophy and left ventricular remodelingRisto Kerkela, Thomas Force
Circulation Research|January 9, 2010
Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeuticsHui Cheng, Thomas Force
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Nature Medicine|March 8, 2008
The weakness of a big heartThomas Force
Circulation Research|January 9, 2010
Introduction to cardiotoxicity review seriesThomas Force
Circulation|March 28, 2012
Double-edged sword of the new cancer therapeuticsThomas Force
Journal of the American College of Cardiology|August 1, 2006
p38 mitogen-activated protein kinase: a future target for heart failure therapy?Risto Kerkela, Thomas Force
Circulation|June 13, 2013
Mechanism-based engineering against anthracycline cardiotoxicityThomas Force, Yibin Wang
Aging|June 28, 2013
Focusing the spotlight on GSK-3 in agingJibin Zhou, Thomas Force
Circulation Research|November 28, 2007
Not all hypertrophy is created equalRonglih Liao, Thomas Force
Drug Discovery Today|July 12, 2008
Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problemThomas Force, Risto Kerkelä
Current Heart Failure Reports|May 11, 2006
Recent insights into cardiac hypertrophy and left ventricular remodelingRisto Kerkela, Thomas Force
Circulation Research|January 9, 2010
Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeuticsHui Cheng, Thomas Force
Pageof 11